Product details
Catalog number BNC682744-100
Price for BNC682744-100
Size / count 1x 100 µL
Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator) . IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL is BNC682744-100.
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL is available here: https://cdn.gentaur.com/products/37/68dd0298061270361e100d3c/msds/bnc682744-100.pdf.
Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferat
If the product is subject to intellectual property protections, we’ll advise on any MTA or usage restrictions before shipping. Let us know your intended end use so we can confirm what’s required upfront.
Conjugation status, such as unconjugated, HRP, FITC, or biotin, is specified in the product name and confirmed on the datasheet.
Assay sensitivity, including the minimum detectable dose, is listed on the datasheet. Kits that are assembled on order typically ship within 2-4 weeks.